Lymphoma Clinical Trials in Philadelphia

Showing 581-599 of 599 trials

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

NCT00112619

RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects, best way to give, and best dose of topotecan when given by intraventricular infusion in treating young patients with neoplastic meningitis due to leukemia, lymphoma, or solid tumors.

Brain and Central Nervous System TumorsCarcinoma of Unknown PrimaryLeukemia+2 more

Pediatric Brain Tumor Consortium19 participantsStarted Aug 2005

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +8 more locations

COMPLETEDPhase 1/2< 1 mile

Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

NCT00002510

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and radiation therapy and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of etoposide plus radiation therapy followed by peripheral stem cell transplantation in treating patients who have non-Hodgkin's lymphoma.

Lymphoma

Temple UniversityStarted Apr 1992

Philadelphia, Pennsylvania, United States

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma Trials in Other Cities

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Other Conditions in Philadelphia